Compare AbbVie Inc (ABBV) vs Aehr Test Systems (AEHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Aehr Test Systems — how do they compare? AbbVie Inc trades at $249.26 (market cap $441.94B), while Aehr Test Systems trades at $130.58 (market cap $3.82B). The key difference: AbbVie Inc is far larger — about 115.7× Aehr Test Systems's market cap, and AbbVie Inc pays a 2.77% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| ABBV | AEHR | |
|---|---|---|
Market Cap | $441.94B | $3.82B |
Sector | Health | Technology |
52-Week High | $263.58 | $117.18 |
52-Week Low | $197.38 | $17.38 |
Enterprise Value | $506.19B | $3.72B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
AEHR Test Systems stock trades at $129.70, up 22.13% in the past 24 hours, with a bullish technical signal from moving averages and strong momentum. Recent earnings beats and a $22 million AI processor order (Accesswire, August 12, 2026) highlight growth potential, though negative net income margins and high P/S of 71.87 reflect valuation concerns amid rapid revenue expansion.
Outlook is mixed: strong AI-driven demand and record bookings support upside, but profitability challenges, insider selling, and customer concentration pose risks. Analyst consensus is cautious with 33% buy ratings, indicating tempered optimism despite technical strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →
